THIS report describes our experience with kanamycin§ in the treatment of 25 severe and acute infections in the adult. In general, the new antimicrobial agent has been administered for two kinds of infections—those caused by penicillin-resistant staphylococci and those resulting from invasion by a number of common gram-negative bacilli. Since the results of therapy are encouraging in both areas this preliminary report seems warranted. The drug deserves wider clinical trial, however, before final decision about its efficacy in management of human infections can be made.Extensive studies of the pharmacologic properties of kanamycin in man and animals have been reported, . . .
No takes yet. Share an insight, caveat, or question.
Bunn et al. (1958) studied this question.